JAK2 and hepatocellular carcinoma: In addition, for three patients with advanced hepatocellular carcinoma whom received the study treatment with sorafenib as part of standard treatment for their disease, inhibition of target kinases related to treatment response in 1 patient, based on reduced activity of known and predicted substrates of MAP2K, EGFR and JAK2 (Figure S5) was observed, while activity persisted in two patients with progressive disease.